Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.63 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.59 |
| ▸ | TOP2A | P11388 | 5/20 | 0.46 |
| ▸ | TOP2B | Q02880 | 5/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7978648 | 0.96 | STAT3 (0.59) | STAT3ADRB2TOP2ATOP2BKCNH2 | |
| SCHEMBL5704368 | 0.90 | STAT3 (0.56) | STAT3ADRB2TOP2ATOP2BKCNH2 | |
| SCHEMBL30863948 | 0.90 | STAT3 (0.56) | STAT3ADRB2TOP2ATOP2BKCNH2 | |
| SCHEMBL9186289 | 0.90 | ADRB2 (0.59) | STAT3ADRB2TOP2ATOP2BKCNH2 | |
| SCHEMBL29492858 | 0.88 | ADRB2 (0.68) | STAT3ADRB2TOP2ATOP2BKCNH2 | |
| SCHEMBL2844967 | 0.88 | ADRB2 (0.68) | STAT3ADRB2TOP2ATOP2BKCNH2 | |
| SCHEMBL2670429 | 0.88 | STAT3 (0.61) | STAT3ADRB2KMT2AKDM4EALDH1A1 | |
| SCHEMBL3551375 | 0.88 | STAT3 (0.61) | STAT3ADRB2KMT2AKDM4EALDH1A1 | |
| SCHEMBL13341767 | 0.88 | STAT3 (0.61) | STAT3ADRB2KMT2AKDM4EALDH1A1 | |
| SCHEMBL10471225 | 0.87 | STAT3 (0.53) | STAT3ADRB2TOP2ATOP2BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107987074-B | Synthetic method of prafloxacin | 浙江美诺华药物化学有限公司 | 2020-12-29 | — | — | CN | disclosed |
| EP-1669354-B1 | 8-CYANOQUINOLONECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1669354-B1 | 8-CYANOQUINOLONECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-7723524-B2 | 8-cyanoquinolonecarboxylic acid derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-05-25 | — | — | US | disclosed |
| US-7723524-B2 | 8-cyanoquinolonecarboxylic acid derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-05-25 | — | — | US | disclosed |
| US-7723524-B2 | 8-cyanoquinolonecarboxylic acid derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-05-25 | — | — | US | disclosed |
| US-20080255190-A1 | 8-Cyanoquinolonecarboxylic Acid Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080255190-A1 | 8-Cyanoquinolonecarboxylic Acid Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080255190-A1 | 8-Cyanoquinolonecarboxylic Acid Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-10-16 | — | — | US | disclosed |
| EP-1669354-A1 | 8-CYANOQUINOLONECARBOXYLIC ACID DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-6432948-B1 | ANTIULCER AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-08-13 | — | — | US | disclosed |
| EP-1215202-A1 | Intermediates for the preparation of possibly substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-(4.3.0)-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolin carboxylic acids and their derivatives | BAYER AG (DE) | 2002-06-19 | — | — | EP | disclosed |
| US-6323213-B1 | ANTIBIOTICS, BACTERICIDES FOR VETERINARY MEDICINE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-11-27 | — | — | US | disclosed |
| US-20010036941-A1 | Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolonecarboxylic acid and -naphthyridonecarboxylic acid derivatives for the therapy of Helicobacter pylori infections and associated gastroduodenal disorders | PETERSEN UWE (DE) | 2001-11-01 | — | — | US | disclosed |
| US-6288081-B1 | Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolone carboxylic acid and naphthyridone carboxylic acid derivatives for treating Helicobacter pylori infections and the gastroduodenal diseases associated therewith | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-11 | — | — | US | disclosed |
| US-6278013-B1 | AS CHEMICAL INTERMEDIATES FOR PREPARING QUINOLINECARBOXYLIC ACID DERIVATIVE ANTIBIOTICS USED IN VETERINARY MEDICINE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-08-21 | — | — | US | disclosed |
| US-6229017-B1 | BY ACYLATION AND CYCLIZATION OF A BENZOYL CHLORIDE OR NICOTINOYL CHLORIDE IN THE PRESENCE OF A NON-POLAR TO SLIGHTLY POLAR SOLVENT WITHOUT SEPARATION OF CHEMICAL INTERMEDIATES DURING PROCESS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-05-08 | — | — | US | disclosed |
| US-6133260-A | Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2000-10-17 | — | — | US | disclosed |
| EP-0882049-A1 | POSSIBLY SUBSTITUTED 8-CYANO-1-CYCLOPROPYL-7-(2,8-DIAZABICYCLO- 4.3.0]-NONAN-8-YL)-6-FLUORO-1,4-DIHYDRO-4-OXO-3-QUINOLIN CARBOXYLIC ACIDS AND THEIR DERIVATIVES | BAYER AG (DE) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997031001-A1 | POSSIBLY SUBSTITUTED 8-CYANO-1-CYCLOPROPYL-7-(2,8-DIAZABICYCLO-[4.3.0]-NONAN-8-YL)-6-FLUORO-1,4-DIHYDRO-4-OXO-3-QUINOLIN CARBOXYLIC ACIDS AND THEIR DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036941-A1 | Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolonecarboxylic acid and -naphthyridonecarboxylic acid derivatives for the therapy of Helicobacter pylori infections and associated gastroduodenal disorders | OXER1, AOC3, PAM | STAT3 1093/4885ADRB2 2223/4885TOP2A 156/4885 |
| US-20080255190-A1 | 8-Cyanoquinolonecarboxylic Acid Derivative | QPCT, ASNS, C3AR1 | STAT3 1608/4885ADRB2 3944/4885TOP2A 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.